Orbicular Pharmaceutical Technologies
Hyderabad
About Orbicular Pharmaceutical Technologies
Orbicular Pharmaceutical Technologies Pvt. Ltd. is a Specialty Pharmaceutical Company that develops niche and complex pharmaceutical dosage forms for licensing to global partners. We are based out of Hyderabad, India and have a state-of-the-art Research facility of 100,000 sq. ft +, accommodating end-to-end capabilities for product delivery across entire product R&D lifecycle. We are a leading Research company backed by a strong team of 300+ competent scientists focussed on making us a one-stop shop to ensure seamless delivery of highly complex products. Our focus is on developing generic pharmaceutical product and 505(b)(2) products with complex chemistry, technological barriers, and limited competition for the global markets. We have extensive experience in developing cutting edge solutions, proprietary processes and technologies to deliver products across multiple delivery platforms, including nano-suspensions, nano-emulsions, liposomes, nanoparticles, and long-acting polymeric injectable suspensions. Our pipeline includes Complex Injectables, Topicals, Ophthalmics, Parenterals, Nasal Sprays /Inhalations and Complex Peptide combination products that target various treatment indications. Our pipeline is characteristic of product domain that is complex, has entry barriers and a is lucrative. We are an outcome driven and value generating organization creating growth partnerships for global pharma players across the entire spectrum of Complex Generics. Our vision is aptly captured in our tag line: Performance Excellence Delivered !
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Total funding: $20.0M
- Funding stage: Private Equity
- Last round: Private Equity (May 2024)
- Website: orbicular.co.in
- Phone: [email protected]
Industries & Categories
Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/orbicular-pharmaceutical-technologies-65191 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.